In a recent study, Dr. Andrea Necchi discussed the results from the phase 2b SunRISe-1 trial of TAR-200 in patients with BCG-unresponsive, high-risk, non-muscle-invasive bladder cancer (NMIBC). The trial evaluated the efficacy of TAR-200 as a monotherapy or in combination with cetrelimab in patients with BCG-unresponsive high-risk NMIBC. The findings from cohort 2 showed that patients treated with TAR-200 monotherapy achieved a complete response (CR) rate of 76.7%, with an investigator-assessed CR rate of 80.0%. The median duration of response (DOR) was not reached, and some complete responders had a DOR of at least 6 months, with 6 patients having a DOR of at least 12 months. These results demonstrate the potential of TAR-200 as an effective treatment option for patients with BCG-unresponsive NMIBC. The ongoing SUNRISE-2 trial is further investigating the use of TAR-200 in patients with MIBC who are ineligible for radical cystectomy or refuse surgery. Additionally, the SUNRISE-3 trial is studying BCG-naive high-risk NMIBC patients, and the SUNRISE-4 trial is focused on the neoadjuvant MIBC setting. [27abc1ec]